Welcome to the upgraded BRAC University Institutional Repository. We are currently organizing collections after a recent system upgrade. Homepage category counters may temporarily show lower numbers while syncing, but over 27,000 repository items remain safe and accessible. Please use the search bar to find theses, scholarly outputs, and institutional documents.

A review on Tyrosine Kinase 2 inhibitors for the treatment of cancer

Simple item page
bracu.degree.levelUndergraduate
bracu.type.groupStudent Works
datacite.rightsOpen Access
dc.contributor.advisorKhair, Nishat Zareen
dc.contributor.authorSumiya, Jannatul Ferdous
dc.contributor.departmentSchool of Pharmacy
dc.date.accessioned2025-01-05T04:28:29Z
dc.date.available2025-01-05T04:28:29Z
dc.date.copyright©2024
dc.date.issued2024-03
dc.descriptionCataloged from PDF version of thesis.
dc.descriptionIncludes bibliographical references (pages 98-105).
dc.descriptionIncludes bibliographical references (pages 42-49).
dc.descriptionThis thesis is submitted in partial fulfillment of the requirements for the degree of Bachelor of Pharmacy, 2024.en_US
dc.description.abstractTyrosine kinase 2 (TYK2) encodes a signaling protein found in cells. TYK2 is being studied as a cancer treatment target due to its role in immune modulation and inflammation. Tyrosine kinase 2 inhibitors block tyrosine kinases, which are essential for cell proliferation, differentiation, and survival. TYK2 inhibitors have been thoroughly investigated for autoimmune diseases but recent development shows potency towards cancer treatments. This review is comprised of an updated compilation of TYK2 inhibitors that are available in the market for the treatment of cancer such as Deucravacitinib, Ruxolitinib, Fedratinib. And some are in the clinical phases such as Ropsacitinib and BMS-986202. However, the existing TYK2 inhibitors can cause resistance and adverse effects due to the. Therefore, more potent and selective inhibitors are needed to be developed. Lastly, this review discusses various approaches of discovering improved TYK2 inhibitors that can be used in the treatment of cancer.en_US
dc.description.degreeBachelor of Pharmacy
dc.description.statementofresponsibilityJannatul Ferdous Sumiya
dc.format.extent52 pages
dc.identifier.otherID 19346048
dc.identifier.urihttp://hdl.handle.net/10361/25035
dc.language.isoenen_US
dc.publisherBRAC Universityen_US
dc.rightsBrac University theses are protected by copyright. They may be viewed from this source for any purpose, but reproduction or distribution in any format is prohibited without written permission.
dc.subjectTyrosine Kinase 2en_US
dc.subjectTyrosine Kinase 2 inhibitorsen_US
dc.subjectCanceren_US
dc.subjectProtein kinaseen_US
dc.subjectDeucravacitiniben_US
dc.subjectFedratiniben_US
dc.subject.lcshCancer.
dc.subject.lcshProtein-tyrosine kinase--Inhibitors.
dc.subject.lcshProtein kinase.
dc.titleA review on Tyrosine Kinase 2 inhibitors for the treatment of canceren_US
dc.typeThesisen_US

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
19346048_PHR.pdf
Size:
1006.47 KB
Format:
Adobe Portable Document Format
Description:
Download

License bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

Project report & Thesis (Bachelor of Pharmacy)